Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812234 | 1.00 | HDAC4 (0.51) | HDAC4HDAC1EPHX1TGM2SMN1; SMN2 | |
| SCHEMBL4257798 | 0.99 | HDAC4 (0.49) | HDAC4HDAC1EPHX1TGM2SMN1; SMN2 | |
| SCHEMBL4257792 | 0.99 | HDAC4 (0.49) | HDAC4HDAC1EPHX1TGM2SMN1; SMN2 | |
| SCHEMBL5740541 | 0.93 | HDAC4 (0.54) | HDAC4HDAC1EPHX1TGM2SMN1; SMN2 | |
| SCHEMBL2808344 | 0.88 | HDAC4 (0.49) | HDAC4HDAC1EPHX1SMN1; SMN2CASP1 | |
| SCHEMBL2808340 | 0.88 | HDAC4 (0.49) | HDAC4HDAC1EPHX1SMN1; SMN2CASP1 | |
| SCHEMBL8158076 | 0.85 | HDAC4 (0.47) | HDAC4HDAC1EPHX1SMN1; SMN2CASP1 | |
| SCHEMBL693600 | 0.84 | HDAC4 (0.45) | HDAC4HDAC1EPHX1TGM2SMN1; SMN2 | |
| SCHEMBL27780890 | 0.83 | HDAC4 (0.54) | HDAC4HDAC1EPHX1SMN1; SMN2ITGB3 | |
| SCHEMBL13268215 | 0.82 | CTSK (0.43) | HDAC4HDAC1EPHX1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477980-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-06-08 | — | — | EP | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| EP-2477980-A1 | HCV PROTEASE INHIBITORS | Taigen Biotechnology Co., Ltd. (TW) | 2012-07-25 | — | — | EP | disclosed |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-07-21 | — | — | US | disclosed |
| WO-2011034518-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20040248779-A1 | Process for the preparation of macrocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | HDAC4 2827/4885HDAC1 1161/4885EPHX1 1057/4885 |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | HDAC4 2284/4885HDAC1 1185/4885EPHX1 1246/4885 |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | HAVCR2, RNASE1, SERPINB1 | HDAC4 2073/4885HDAC1 1692/4885EPHX1 1158/4885 |
| US-20040248779-A1 | Process for the preparation of macrocyclic compounds | CCND2, CYP1B1, PRMT1 | HDAC4 2448/4885HDAC1 879/4885EPHX1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.